Gene Variant Detail

Gene MET
Variant amp
Impact List none
Protein Effect no effect
Gene Variant Descriptions MET amp indicates an increased number of copies of the MET gene. However, the mechanism causing the increase is unspecified.
Associated Drug Resistance

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

No Variant Reference Transcript is Available.
No transcript is Available.

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
MET amp MET D1228N triple-receptor negative breast cancer predicted - resistant Crizotinib Case Reports/Case Series Actionable In a clinical case study, MET D1228N was identified as an acquired mutation at disease progression in a patient with triple-receptor negative breast cancer harboring a 30-fold amplification of MET, after initial response to Xalkori (crizotinib) treatment (Proceedings of the American Association for Cancer Research, Vol 60, Mar 2019, Abstract #1317). detail...
MET amp MET D1228N triple-receptor negative breast cancer predicted - sensitive Cabozantinib Case Reports/Case Series Actionable In a clinical case study, Cometriq (Cabometyx, cabozantinib) treatment resulted in stable diseases in a patient with triple-receptor negative breast cancer harboring a 30-fold amplification of MET whom developed resistance to Xalkori (crizotinib) after acquiring MET D1228N (Proceedings of the American Association for Cancer Research, Vol 60, Mar 2019, Abstract #1317). detail...
BRAF V600E MET amp rectum mucinous adenocarcinoma predicted - resistant Panitumumab + Vemurafenib Case Reports/Case Series Actionable In a clinical case study, a patient with microsatellite-stable mucinous rectal cancer harboring BRAF V600E eventually developed resistance to Vectibix (panitumumab) and Zelboraf (vemurafenib) combination therapy, potentially due to acquiring amplification of MET (PMID: 27325282). 27325282
BRAF V600E MET amp colorectal cancer predicted - resistant Alpelisib + Cetuximab + Encorafenib Case Reports/Case Series Actionable In a preclinical study, emergence of MET amplification was detected in colorectal cancer cells harboring BRAF V600E that acquired resistance to Alpelisib (BYL719), Erbitux (cetuximab), and Braftovi (encorafenib) combination treatment in culture (PMID: 27325282). 27325282
BRAF V600E MET amp rectum mucinous adenocarcinoma predicted - sensitive Crizotinib + Vemurafenib Case Reports/Case Series Actionable In a clinical case study, a patient with microsatellite-stable mucinous rectal cancer harboring BRAF V600E and acquired MET amplification responded to the combination treatment of Xalkori (crizotinib) and Zelboraf (vemurafenib), resulting in a rapid clinical and metabolic response (PMID: 27325282). 27325282
ERBB2 amp MET amp gastric adenocarcinoma predicted - resistant Fluorouracil + Leucovorin + Oxaliplatin + Trastuzumab Case Reports/Case Series Actionable In a clinical case study, a patient with ERBB2 (HER2) and MET co-amplified gastric adenocarcinoma was insensitive to Herceptin (trastuzumab) and FOLFOX combination treatment (PMID: 26432108). 26432108
ERBB2 amp MET amp gastric adenocarcinoma predicted - resistant Bevacizumab + Capecitabine + Oxaliplatin + Trastuzumab Case Reports/Case Series Actionable In a clinical case study, a patient with ERBB2 (HER2) amplified gastric adenocarcinoma progressed rapidly when treated with Herceptin (trastuzumab) with Xeloda (capecitabine), Eloxatin (oxaliplatin), and Avastin (bevacizumab), and reprofiling of the tumor revealed co-amplification of MET (PMID: 26432108). 26432108
ERBB2 amp MET amp esophageal carcinoma sensitive Crizotinib + Lapatinib Preclinical - Cell culture Actionable In a preclinical study, a human esophageal carcinoma cell line harboring amplification of ERBB2 (HER2) and MET was sensitive to inhibition by Tykerb (lapatinib) and Xalkori (crizotinib) in culture (PMID: 26432108). 26432108
ERBB2 amp MET amp gastroesophageal junction adenocarcinoma sensitive Crizotinib + Lapatinib Preclinical - Cell culture Actionable In a preclinical study, the combination of Xalkori (crizotinib) and Tykerb (lapatinib) inhibited the growth of gastroesophageal adenocarcinoma cells with ERBB2 (HER2) and MET amplification in culture (PMID: 25350844). 25350844
ERBB2 amp MET amp gastric adenocarcinoma predicted - sensitive Crizotinib + Paclitaxel + Trastuzumab Case Reports/Case Series Actionable In a clinical case study, a patient with ERBB2 (HER2) and MET co-amplified gastric adenocarcinoma had near complete regression of the disease after 2 months of treatment with Herceptin (trastuzumab), Xalkori (crizotinib) and weekly Taxol (paclitaxel) (PMID: 26432108). 26432108
ERBB2 amp MET amp gastric adenocarcinoma predicted - resistant AMG 337 Case Reports/Case Series Actionable In a clinical case study, a patient with ERBB2 (HER2) and MET co-amplified gastric adenocarcinoma did not respond to AMG 337 therapy (PMID: 26432108). 26432108
ERBB2 amp MET amp esophageal carcinoma resistant Lapatinib Preclinical Actionable In a preclinical study, a human esophageal carcinoma cell line harboring amplification of ERBB2 and MET was resistant to Tykerb (lapatinib) in culture (PMID: 26432108). 26432108
ERBB2 amp MET amp esophagus adenocarcinoma sensitive Crizotinib + Lapatinib Preclinical - Cell culture Actionable In a preclinical study, the combination of Xalkori (crizotinib) and Tykerb (lapatinib) worked synergistically to inhibit growth of an esophageal adenocarcinoma cell line with ERBB2 (HER2) and MET amplification in culture (PMID: 27595477). 27595477
ERBB2 amp MET amp esophageal carcinoma resistant Crizotinib Preclinical - Cell culture Actionable In a preclinical study, a human esophageal carcinoma cell line harboring amplification of ERBB2 (HER2) and MET was resistant to Xalkori (crizotinib) in culture (PMID: 26432108). 26432108
KRAS G12A MET amp lung cancer resistant SAR125844 Preclinical - Cell culture Actionable In a preclinical study, MET amplified lung cancer cells harboring KRAS G12A were insensitive to SAR125844-mediated growth inhibition in culture (PMID: 25504634). 25504634
KRAS G12A MET amp lung cancer resistant AMG 337 Preclinical - Cell culture Actionable In a preclinical study, a MET-amplified lung cancer cell line harboring KRAS G12A was not sensitive to growth inhibition by AMG 337 in culture (PMID: 27196782). 27196782
FGFR1 amp MET amp lung cancer sensitive AZD4547 + Crizotinib Preclinical - Cell culture Actionable In a preclinical study, AZD4547 and Xalkori (crizotinib) synergistically inhibited proliferation of FGFR1 amplified lung cancer cells that acquired resistance to AZD4547 through MET amplification in culture (PMID: 27429073). 27429073
FGFR1 amp MET amp lung squamous cell carcinoma predicted - resistant BGJ398 Phase I Actionable In a Phase I trial, MET amplification was detected in a squamous cell lung cancer patient harboring FGFR1 amplification whose disease relapsed after 17 months of BGJ398 treatment, supporting a role of MET amplification in drug resistance in FGFR1-amplified lung cancer (PMID: 28630215). 28630215
FGFR1 amp MET amp lung cancer resistant AZD4547 Preclinical - Cell culture Actionable In a preclinical study, MET amplification was identified as the mechanism mediating acquired AZD4547 resistance in a FGFR1 amplified lung cancer cell line in culture (PMID: 27429073). 27429073
MET amp MET del exon14 MET D1228N MET G1163R MET Y1230H MET Y1230S lung adenocarcinoma predicted - resistant Crizotinib Case Reports/Case Series Actionable In a clinical case study, a patient with lung adenocarcinoma harboring MET deletion exon 14 responded to Xalkori (crizotinib), demonstrating a near complete response at 3 months, however, after 9 months progression ensued and a re-biospy identified MET del exon14, MET amplification, MET D1228N, MET Y1230H, MET Y1230S, and MET G1163R (PMID: 28522754). 28522754
MET amp MET del exon14 MET D1228N MET G1163R MET Y1230H MET Y1230S lung adenocarcinoma predicted - resistant Crizotinib Case Reports/Case Series Actionable In a clinical case study, a lung adenocarcinoma patient harboring MET deletion exon 14 and MET amplification demonstrated resistance to Xalkori (crizotinib), and the patient was found to have acquired MET Y1230H, MET D1228N, MET Y1230S, and MET G1163R (PMID: 28765324). 28765324
MET amp MET del exon14 lung cancer predicted - sensitive TPX-0022 Preclinical - Pdx Actionable In a preclinical study, TPX-0022 treatment resulted in tumor regression in patient-derived xenograft (PDX) models of lung cancer harboring MET amplification and MET exon 14 deletion (Proceedings of the American Association for Cancer Research, Vol 60, Mar 2019, Abstract #1321). detail...
MET amp MET del exon14 lung adenocarcinoma predicted - sensitive Cabozantinib Case Reports/Case Series Actionable In a clinical case study, a patient with lung adenocarcinoma harboring a MET exon 14 skipping mutation and MET amplification demonstrated a complete response via PERCIST criteria when treated with Cometriq (Cabometyx, cabozantinib) (PMID: 25971939). 25971939
MET amp MET del exon14 lung non-small cell carcinoma sensitive SCC244 Preclinical - Pdx Actionable In a preclinical study, non-small cell lung carcinoma patient derived xenograft (PDX) models co-harboring MET amplification and MET deletion of exon 14 were sensitive to SCC244 treatment, demonstrating a complete response in four and a partial response in another four (PMID: 29237805). 29237805
MET amp MET del exon14 lung adenocarcinoma predicted - sensitive Crizotinib Case Reports/Case Series Actionable In a clinical case study, a lung adenocarcinoma patient co-harboring MET exon 14 deletion and MET amp was sensitive to Xalkori (crizotinib), demonstrating a partial response for 8 months (PMID: 28765324). 28765324
MET amp MET del exon14 lung non-small cell carcinoma sensitive Glesatinib Preclinical - Pdx Actionable In a preclinical study, Glesatinib (MGCD265) treatment resulted in tumor regression in patient-derived xenograft (PDX) models of non-small cell lung cancer harboring deletion of MET exon 14 and varying degrees of MET amplification (PMID: 28765324). 28765324
MET amp MET del exon14 lung cancer sensitive Glesatinib Preclinical - Pdx Actionable In a preclinical study, a lung cancer patient-derived xenograft (PDX) model harboring MET amplification and MET exon 14 deletion demonstrated tumor regression when treated with Glesatinib (MGCD265) (PMID: 28765324). 28765324
ALK rearrange MET amp lung adenocarcinoma sensitive Crizotinib Case Reports/Case Series Actionable In a clinical case study, a lung adenocarcinoma patient harboring an ALK rearrangement who developed resistance to Alecensa (alectinib) likely due to acquisition of MET amplification, responded well to treatment with Xalkori (crizotinib), demonstrating a radiological response after 12 days (PMID: 24128725, PMID: 24518097). 24128725 24518097
ALK rearrange MET amp lung adenocarcinoma resistant Alectinib Case Reports/Case Series Actionable In a clinical case study, a lung adenocarcinoma patient harboring an ALK rearrangement developed resistance to Alecensa (alectinib) treatment, and subsequently was found to harbor amplification of MET (PMID: 24128725, PMID: 24518097). 24518097 24128725
KRAS G12V MET amp carcinoma predicted - sensitive Crizotinib Case Reports/Case Series Actionable In a clinical case study, a patient with a carcinoma of unknown primary harboring MET amplification and KRAS G12V demonstrated a durable response following treatment with Xalkori (crizotinib) (PMID: 25232318). 25232318
KRAS G12D MET amp esophagus adenocarcinoma predicted - resistant AMG 337 Case Reports/Case Series Actionable In a clinical case study, a patient with a MET amplified adenocarcinoma of the distal esophagus responded to AMG 337 treatment for 2 years, but developed resistance upon emergence of KRAS G12D (PMID: 26432108). 26432108
ERBB2 over exp MET amp MET R988C stomach cancer predicted - resistant Trastuzumab Clinical Study - Cohort Actionable n a clinical study (AMNESIA-1), assessment of pre-treatment tumor samples from ERBB2 (HER2)-positive (defined as HER2 IHC 3+ or HER2 IHC 2+/ISH+) gastric or gastroesophageal cancer patients identified MET R988C and amplification of MET in 1 patient demonstrating primary resistance to Herceptin (trastuzumab) (PMID: 29208673). 29208673
MET amp MET del exon14 MET D1228N MET G1163R MET L1195V lung adenocarcinoma predicted - resistant Glesatinib Case Reports/Case Series Actionable In a clinical case study, a lung adenocarcinoma patient previously harboring MET amp, MET deletion exon 14, MET D1228N, MET Y1230H, MET Y1230S, and MET G1163R demonstrated a decrease in lesion size when treated with Glesatinib (MGCD265), however, progression ensued and plasma testing indicated the patient lost Y1230H and Y1230S, but acquired MET L1195V (PMID: 28765324). 28765324
BRAF V600E KRAS amp MET amp colorectal cancer predicted - resistant Panitumumab + Vemurafenib Case Reports/Case Series Actionable In a clinical case study, a patient with BRAF V600E colorectal cancer developed progressive disease after achieving stable disease for 32 weeks with Vectibix (panitumumab) and Zelboraf (vemurafenib) combination treatment, KRAS and MET amplification were identified as acquired alterations at the time of progression (PMID: 28951457). 28951457
ALK rearrange ALK I1171N MET amp lung non-small cell carcinoma predicted - resistant Brigatinib Case Reports/Case Series Actionable In a clinical case study, MET amplification was identified together with a pre-existing ALK I1171N at disease progression while on Alunbrig (brigatinib) treatment in a patient with ALK-positive non-small cell lung cancer (PMID: 29935304). 29935304
MET amp MET over exp lung non-small cell carcinoma sensitive Altiratinib Preclinical - Cell culture Actionable In a preclinical study, Altiratinib (DCC-2701) inhibited Met phosphorylation and proliferation of a non-small cell lung cancer cell line with MET amplification and overexpression in culture (PMID: 26285778). 26285778
MET amp MET over exp stomach carcinoma sensitive K252a Preclinical Actionable In preclinical studies, a MET amplified, gastric carcinoma cell over expressing Met was sensitive to K252a treatment in both culture and mouse model experiments (PMID: 12118367). 12118367
MET amp MET over exp stomach cancer sensitive Altiratinib Preclinical - Cell line xenograft Actionable In a preclinical study, Altiratinib (DCC-0701) inhibited Met phosphorylation and proliferation of a gastric cancer cell line with MET amplification and over expression in culture, and inhibited tumor growth and induced tumor regression in xenograft models (PMID: 26285778). 26285778
MET amp stomach cancer sensitive SGX523 Preclinical - Cell line xenograft Actionable In a preclinical study, SGX523 inhibited Met signaling and proliferation of MET amplified gastric cancer cells in culture, resulted in tumor growth inhibition in cell line xenograft models (PMID: 19934279). 19934279
MET amp stomach cancer sensitive AMG 337 Preclinical - Cell line xenograft Actionable In a preclinical study, AMG 337 inhibited growth of gastric cancer cell lines in culture, and inhibited growth and induced regression of tumors in MET-amplified gastric cancer cell line xenograft models (PMID: 27196782). 27196782
MET amp Advanced Solid Tumor predicted - sensitive SAR125844 Phase I Actionable In a Phase I trial, SAR125844 treatment in advanced solid tumor patients harboring a MET amplification was well-tolerated and resulted in a partial response in 17% (5/29) of patients, including patients with non-small cell lung carcinoma, and stable disease in 59% (17/29) of patients (PMID: 29145039; NCT01391533). detail... 29145039
MET amp lung non-small cell carcinoma sensitive Capmatinib Phase I Actionable In a Phase I trial, Capmatinib (INC280) treatment resulted in partial response in 63% (5/8) of MET amplified non-small cell lung carcinoma patients (J Clin Oncol 34, 2016 (suppl; abstr 9067)). detail...
MET amp lung non-small cell carcinoma sensitive TAE226 Preclinical Actionable In a preclinical study, TAE226 treatment inhibited proliferation of non-small cell lung carcinoma cell lines harboring MET amplification in culture (PMID: 26090892). 26090892
MET amp colorectal cancer resistant Cetuximab Case Reports/Case Series Actionable In a clinical case study, MET amplification was associated with resistance to Erbitux (cetuximab) in 2 colorectal cancer patients, and in patient-derived xenograft (PDX) models (PMID: 23729478). 23729478
MET amp stomach cancer sensitive KTN0073-IgG2 Preclinical - Cell line xenograft Actionable In a preclinical study, KTN0073-IgG2 inhibited MET phosphorylation and induced MET degradation, and inhibited growth of a MET-amplified gastric cancer cell line in culture and in xenograft models (PMID: 27550450). 27550450
MET amp lung non-small cell carcinoma predicted - sensitive PP-121 Preclinical - Cell culture Actionable In a preclinical study, the multitarget kinase inhibitor PP-121 inhibited survival of MET amplified non-small cell lung cancer cells that acquired resistance to SGX532 through activation of multiple kinase signaling pathways in culture (PMID: 26483207). 26483207
MET amp lung non-small cell carcinoma predicted - sensitive Alvespimycin Preclinical - Cell line xenograft Actionable In a preclinical study, disruption of multiple kinases with Hsp90 inhibitor Alvespimycin inhibited survival of MET amplified non-small cell lung cancer cells that acquired resistance to SGX532 through activation of multiple kinase signaling pathways in culture and in cell line xenograft models (PMID: 26483207). 26483207
MET amp stomach cancer sensitive SCC244 Preclinical - Cell line xenograft Actionable In a preclinical study, SCC244 inhibited Met activity, downstream signaling, and cell proliferation in gastric cancer cells harboring MET amplification in culture, and inhibited tumor growth in cell line xenograft models (PMID: 29237805). 29237805
MET amp lung non-small cell carcinoma predicted - resistant Osimertinib Case Reports/Case Series Actionable In a clinical case study, two patients with non-small cell lung cancer harboring EGFR T790M progressed after Tagrisso (osimertinib) treatment, and were found to have lost EGFR T790M and acquired a MET amplification (PMID: 30268451). 30268451
MET amp lung non-small cell carcinoma predicted - resistant Osimertinib Case Reports/Case Series Actionable In a clinical case study, a patient with non-small cell lung cancer harboring EGFR amplification and EGFR T790M progressed after Tagrisso (osimertinib) treatment, and was found to have lost the EGFR mutations and acquired a MET amplification (PMID: 30268451). 30268451
MET amp Advanced Solid Tumor sensitive ABT-700 Phase I Actionable In a Phase I trial, ABT-700 demonstrated safety and preliminary efficacy in patients with MET-amplified advanced solid tumors, including a patient with ovarian cancer (J Clin Oncol 32:5s, 2014 (suppl; abstr 2507)). detail...
MET amp stomach cancer sensitive Telisotuzumab vedotin Preclinical - Cell line xenograft Actionable In a preclinical study, ABBV-399 inhibited growth of MET-amplified gastric cancer cell in culture, and induced tumor regression in a MET-amplified gastric cancer cell line xenograft model (PMID: 27573171). 27573171
MET amp stomach cancer sensitive M-COPA Preclinical - Cell line xenograft Actionable In a preclinical study, M-COPA reduced Met cell surface expression and downstream signaling and decreased growth of MET-amplified gastric cancer cell lines in culture, and demonstrated antitumor activity in MET-amplified gastric cancer cell line xenograft models (PMID: 27197184). 27197184
MET amp stomach carcinoma sensitive EMD 1214063 Preclinical - Cell line xenograft Actionable In a preclinical study, EMD 1214063 induced tumor regression in mouse cell line xenograft models of gastric carcinoma harboring MET amplification (PMID: 23553846). 23553846
MET amp gastroesophageal cancer predicted - sensitive AMG 337 Phase I Actionable In a Phase I trial, AMG 337 treatment resulted in complete response in 10% (1/10), partial response in 40% (4/10), and stable disease in 20% (2/10) of patients with MET amplified gastroesophageal cancer (J Clin Oncol 33, no. 3_suppl (January 20 2015) 1-1; NCT01253707). detail...
MET amp Advanced Solid Tumor not applicable N/A Clinical Study Emerging In a retrospective study, advanced solid tumor patients harboring MET amplification demonstrated worse overall survival (7.23 months) comparing to patients without MET amplification (8.62 months) (PMID: 25326232), suggesting that this may serve as a future prognostic biomarker. 25326232
MET amp Advanced Solid Tumor sensitive Emibetuzumab Preclinical Actionable In a preclinical study, Emibetuzumab (LY2875358) treatment inhibited MET activation and proliferation of tumor cells with MET amplification in culture, and inhibited growth in MET-amplified tumor xenograft models (PMID: 25231402). 25231402
MET amp liver cancer sensitive Crizotinib Preclinical - Pdx Actionable In a preclinical study, Xalkori (crizotinib) inhibited tumor grow in patient-derived xenograft models of MET amplified liver cancer (PMID: 26483207). 26483207
MET amp stomach cancer sensitive TAS-115 Preclinical Actionable In a preclinical study, MET amplified gastric cancer cell lines were sensitive to TAS-115, resulting in suppression of cell proliferation in culture (PMID: 24140932). 24140932
MET amp lung non-small cell carcinoma sensitive KTN0073-IgG2 Preclinical - Cell culture Actionable In a preclinical study, KTN0073-IgG2 inhibited MET phosphorylation and induced MET degradation, and inhibited proliferation of a MET-amplified non-small cell lung cancer cell line in culture (PMID: 27550450). 27550450
MET amp stomach cancer predicted - sensitive TPX-0022 Preclinical - Cell line xenograft Actionable In a preclinical study, TPX-0022 inhibits phosphorylation of Met and downstream signaling, resulted in growth inhibition of MET amplified gastric cancer cell lines in culture and in cell line xenograft models (Proceedings of the American Association for Cancer Research, Vol 60, Mar 2019, Abstract #1321). detail...
MET amp colorectal cancer sensitive JNJ 38877605 Preclinical - Pdx Actionable In a preclinical study, JNJ-38877605 inhibited tumor growth in colorectal cancer patient-derived xenograft models with MET amplification (PMID: 23729478). 23729478
MET amp lung cancer sensitive Golvatinib Preclinical - Cell line xenograft Actionable In a preclinical study, Golvatinib (E7050) inhibited Met and Kdr (Vegfr2) phosphorylation, resulted in growth inhibition of lung cancer cells in culture and tumor regression in cell line xenograft models (PMID: 19832844). 19832844
MET amp lung squamous cell carcinoma sensitive SCC244 Preclinical - Cell line xenograft Actionable In a preclinical study, SCC244 inhibited Met activity, downstream signaling, and cell proliferation in lung squamous cell carcinoma cells harboring MET amplification in culture, and inhibited tumor growth in cell line xenograft models (PMID: 29237805). 29237805
MET amp lung non-small cell carcinoma sensitive SGX523 Preclinical - Cell culture Actionable In a preclinical study, SGX523 inhibited survival of MET-amplified non-small cell lung cancer cells in culture (PMID: 26483207). 26483207
MET amp stomach cancer sensitive Golvatinib Preclinical - Cell line xenograft Actionable In a preclinical study, Golvatinib (E7050) inhibited Met and Kdr (Vegfr2) phosphorylation, resulted in growth inhibition of gastric cancer cell lines in culture and in cell line xenograft models (PMID: 19832844). 19832844
MET amp Advanced Solid Tumor conflicting AMG 337 Clinical Study - Cohort Actionable In a retrospective study, treatment with Met inhibitors, including AMG 337 or EMD 1204831, resulted in stable disease in 29% (2/7) of advanced solid tumor patients harboring MET amplification while 10% (14/134) of MET non-amplified patients achieved partial response (PMID: 25326232). 25326232
MET amp Advanced Solid Tumor conflicting AMG 337 Phase I Actionable In a Phase I trial, AMG 337 treatment resulted in an objective response rate (ORR) of 29.6% (8/27) and a median duration of response (mDOR) of 197 days in patients with MET amplified advanced solid tumors, compared to an ORR of 9.9% (11/111) and mDOR of 202 days in all patients (PMID: 30425090; NCT01253707). 30425090
MET amp lung non-small cell carcinoma sensitive EMD 1214063 Preclinical - Cell line xenograft Actionable In a preclinical study, EMD 1214063 induced tumor regression in mouse cell line xenograft models of non-small cell lung carcinoma harboring MET amplification (PMID: 23553846). 23553846
MET amp stomach cancer sensitive TAE226 Preclinical Actionable In a preclinical study, TAE226 treatment inhibited proliferation of gastric cancer cell lines harboring MET amplification in culture (PMID: 26090892). 26090892
MET amp hepatocellular carcinoma sensitive AMG 337 Preclinical - Pdx & cell culture Actionable In a preclinical study, AMG 337 inhibited Met phosphorylation and growth of hepatocellular carcinoma (HCC) cell lines with MET amplification in culture, and inhibited tumor growth in MET-amplified HCC patient-derived xenograft models (PMID: 27196749). 27196749
MET amp lung non-small cell carcinoma sensitive BEZ235 + Selumetinib Preclinical - Cell line xenograft Actionable In a preclinical study, Selumetinib (AZD6244) in combination with BEZ235, synergistically inhibited proliferation of an Iressa (gefitinib)-resistant NSCLC cell line harboring MET amplification in culture and in cell line xenograft models (PMID: 24939055). 24939055
MET amp lung non-small cell carcinoma predicted - sensitive Ganetespib Preclinical - Cell culture Actionable In a preclinical study, disruption of multiple kinases with Hsp90 inhibitor Ganetespib inhibited survival of MET amplified non-small cell lung cancer cells that acquired resistance to SGX532 through activation of multiple kinase signaling pathways in culture (PMID: 26483207). 26483207
MET amp lung non-small cell carcinoma predicted - sensitive Dasatinib Preclinical - Cell culture Actionable In a preclinical study, the multitarget kinase inhibitor Sprycel (dasatinib) inhibited survival of MET amplified non-small cell lung cancer cells that acquired resistance to SGX532 through activation of multiple kinase signaling pathways in culture (PMID: 26483207). 26483207
MET amp gastroesophageal adenocarcinoma predicted - sensitive AMG 337 Phase II Actionable In a Phase II trial, AMG 337 treatment resulted in an objective response rate of 18% (8/45, 8 partial responses) and stable disease in 36% (16/45) of patients with MET-amplified gastroesophageal adenocarcinoma (PMID: 30366938; NCT02016534). 30366938
MET amp lung cancer sensitive SAR125844 Preclinical - Cell culture Actionable In a preclinical study, SAR125844 inhibited Met signaling, leading to growth inhibition of MET amplified lung cancer cells in culture (PMID: 25504634). 25504634
MET amp stomach cancer sensitive Glesatinib Preclinical - Cell line xenograft Actionable In a preclinical study, Glesatinib (MGCD265) treatment resulted in tumor regression in MET-amplified gastric cancer cell line xenograft models (PMID: 28765324). 28765324
MET amp lung cancer sensitive Glesatinib Preclinical - Cell culture Actionable In a preclinical study, Glesatinib (MGCD265) inhibited Met phosphorylation and growth of MET-amplified lung cancer cells in culture (PMID: 28765324). 28765324
MET amp Advanced Solid Tumor predicted - sensitive Capmatinib Phase I Actionable In a Phase I trial, INC280 displayed safety and preliminary efficacy in patients with MET dependent solid tumors (J Clin Oncol 32:5s, 2014 (suppl; abstr 2520)). detail...
MET amp stomach cancer sensitive ARGX-111 Phase I Actionable In a Phase I trial, a gastric cancer patient harboring MET amplification was sensitive to treatment with ARGX-111, demonstrating stable disease, a metabolic response, and a decrease in circulating tumor cells (Journal of Clinical Oncology 33, no. 15_suppl (May 2015) 2580-2580). detail...
MET amp lung non-small cell carcinoma predicted - sensitive AMG 337 Case Reports/Case Series Actionable In a Phase I trial, AMG 337 treatment resulted in a partial response in a patient with MET amplified non-small cell lung cancer (PMID: 30425090; NCT01253707). 30425090
MET amp lung non-small cell carcinoma predicted - sensitive AMG 337 Case Reports/Case Series Actionable In a Phase II trial, AMG 337 treatment resulted in no objective response (0/3) and only stable disease in 33% (1/3) of patients with MET-amplified non-small cell lung cancer (PMID: 30366938; NCT02016534). 30366938
MET amp esophagus adenocarcinoma predicted - sensitive AMG 337 Case Reports/Case Series Actionable In a clinical case study, a patient with MET amplified esophageal adenocarcinoma had a partial response to AMG 337 therapy after 2 months of treatment (PMID: 26432108). 26432108
MET amp esophagus adenocarcinoma predicted - sensitive AMG 337 Case Reports/Case Series Actionable In a Phase I trial, AMG 337 treatment resulted in a complete response in a patient with MET amplified esophagus adenocarcinoma at week 33 (PMID: 30425090; NCT01253707). 30425090
MET amp lung non-small cell carcinoma sensitive SCC244 Preclinical - Pdx Actionable In a preclinical study, non-small cell lung carcinoma patient-derived xenograft models harboring MET amplification were sensitive to SCC244, demonstrating inhibition of tumor growth and stable disease (PMID: 29237805). 29237805
MET amp Advanced Solid Tumor decreased response EMD 1204831 Clinical Study - Cohort Actionable In a retrospective study, treatment with Met inhibitors, including AMG 337 or EMD 1204831, resulted in stable disease in 29% (2/7) of advanced solid tumor patients harboring MET amplification while 10% (14/134) of MET non-amplified patients achieved partial response (PMID: 25326232). 25326232
MET amp lung non-small cell carcinoma sensitive Selumetinib Preclinical Actionable In a preclinical study, Selumetinib (AZD6244) suppressed the growth of an Iressa (gefitinib)-resistant NSCLC cell line with MET amplification (PMID: 24939055). 24939055
MET amp hepatocellular carcinoma predicted - sensitive TPX-0022 Preclinical - Pdx Actionable In a preclinical study, TPX-0022 treatment resulted in tumor regression in patient-derived xenograft (PDX) models of hepatocellular carcinoma harboring MET amplification (Proceedings of the American Association for Cancer Research, Vol 60, Mar 2019, Abstract #1321). detail...
MET amp Advanced Solid Tumor sensitive SYM015 Preclinical - Pdx & cell culture Actionable In a preclinical study, Sym015 inhibited growth of cancer cell lines with MET amplification in culture, and inhibited tumor growth in MET-amplified patient-derived xenograft (PDX) models (Cancer Res July 15 2016 (76) (14 Supplement) 1219). detail...
MET amp Advanced Solid Tumor sensitive Tepotinib Phase I Actionable In a Phase I study, Tepotinib (MSC2156119J) demonstrated safety and preliminary efficacy in advanced solid tumor patients with MET amplification (JCO, Vol 33, No 15_suppl (May 20 Supplement), 2015: 2591). detail...
MET amp stomach cancer sensitive SAR125844 Preclinical - Cell line xenograft Actionable In a preclinical study, SAR125844 inhibited Met signaling leading to growth inhibition of MET amplified gastric cancer cell lines in culture and in xenograft models (PMID: 25504634). 25504634
MET amp lung non-small cell carcinoma sensitive BEZ235 Preclinical Actionable In a preclinical study, BEZ235 suppressed the growth of an Iressa (gefitinib)-resistant NSCLC cell line with MET amplification (PMID: 24939055). 24939055
MET amp lung non-small cell carcinoma predicted - sensitive Merestinib Preclinical - Pdx Actionable In a preclinical study, Merestinib (LY2801653) treatment resulted in growth inhibition in patient-derived xenograft (PDX) models of MET-amplified non-small cell lung carcinoma that were resistant to Egfr inhibitors (Cancer Res 2010;70(8 Suppl):Abstract nr 3611). detail...
MET amp lung non-small cell carcinoma sensitive Crizotinib Guideline Actionable Xalkori (crizotinib) is included in guidelines for non-small cell lung cancer patients with high level MET amplification (NCCN.org). detail...
MET amp lung non-small cell carcinoma sensitive Crizotinib Preclinical - Pdx Actionable In a preclinical study, Xalkori (crizotinib) inhibited tumor grow in patient-derived xenograft models of MET amplified non-small cell lung cancer (PMID: 26483207). 26483207
MET amp triple-receptor negative breast cancer predicted - sensitive Crizotinib Case Reports/Case Series Actionable In a clinical case study, Xalkori (crizotinib) treatment resulted in a completed response that sustained for 22 weeks in a patient with triple-receptor negative breast cancer harboring a 30-fold amplification of MET, with MET overexpression and hyperactivity confirmed by IHC (Proceedings of the American Association for Cancer Research, Vol 60, Mar 2019, Abstract #1317). detail...
MET amp papillary renal cell carcinoma sensitive Savolitinib Phase II Actionable In a Phase II trial, treatment with Savolitinib (AZD6094) resulted in an overall response rate (ORR) of 18% (8/44, all partial responses) in the subgroup of patients with MET-driven papillary renal cell carcinoma (PRCC), which included patients with MET amplification, compared to an ORR of 0% (0/46) in patients with MET-independent PRCC (PMID: 28644771; NCT02127710). 28644771
MET amp papillary renal cell carcinoma sensitive Savolitinib Preclinical - Pdx Actionable In a preclinical study, Savolitinib (AZD6094) demonstrated antitumor activity in patient-derived papillary renal cell carcinoma xenograft models harboring MET amplification (PMID: 25779944). 25779944
MET amp stomach cancer no benefit Debio 1347 Preclinical - Cell line xenograft Actionable In a preclinical study, Debio 1347 did not inhibit tumor growth in cell line xenograft models of MET amplified gastric cancer (PMID: 26438159). 26438159
MET amp lung cancer sensitive AMG 337 Preclinical - Cell culture Actionable In a preclinical study, AMG 337 inhibited growth of MET-amplified lung cancer cell lines in culture (PMID: 27196782). 27196782
MET amp TP53 del breast cancer sensitive Crizotinib Preclinical Actionable In a preclinical study, Xalkori (crizotinib) treatment resulted in complete tumor regression in transplant models of TP53-null-luminal breast cancer harboring MET amplification (PMID: 27149990). 27149990
ERBB2 over exp MET amp stomach cancer predicted - resistant Trastuzumab Clinical Study - Cohort Actionable In a clinical study (AMNESIA-1), assessment of pre-treatment tissue from ERBB2 (HER2)-positive gastric or gastroesophageal cancer patients (defined as HER2 IHC 3+ or HER2 IHC 2+/ISH+) identified MET amplification in 1 patient demonstrating primary resistance to Herceptin (trastuzumab) (PMID: 29208673). 29208673